Lawmakers in at least 10 states will consider taxes on makers of opioids in the upcoming legislative session depending on the results of the November election; the numbers may be low, but overdose deaths in Alaska involving fentanyl more than quadrupled in 2017; a new company created by health systems to address drug shortages and high-cost generics is taking shape with a name and a chief executive officer.
Minnesota almost succeeded in taxing makers of opioids, and the state’s lawmakers plan to try again in January 2019. The state isn’t alone—lawmakers in at least 10 other states will consider opioid taxes, reported Kaiser Health News. New York launched its own opioid tax on July 1. The proceeds of the tax would help pay for addiction treatment and prevention, but whether or not states follow through on implementing these taxes will likely depend on if Democrats retake governorships and legislatures in the November election.
The numbers may be low, but overdose deaths in Alaska involving fentanyl more than quadrupled in 2017. The Associated Press reported that 37 people died of fentanyl overdoses last year compared with just 8 the year before. With a small population, Alaska has had one of the highest per-capita death rates for prescription opioid overdoses. As the state’s illegal drug problem has worsened, so has associated crimes, like theft and violence.
In January 2018, a group of health systems announced they would band together to form a nonprofit generic drug company the address shortages and high-cost generics. Now, that company is taking shape. Civica Rx will be independent but include a board of governing members that include health systems like Intermountain Healthcare and the Mayo Clinic, and the company’s CEO will be Martin Van Trieste, a former Amgen executive, according to NPR. The company plans to market 14 common generic drugs, although the names of those drugs haven’t been released yet. They were chosen because they have been in short supply and their prices have recently risen.
Allergies and Asthma Prevalence Rise With Climate Change Extremes and Pollutants
June 30th 2025Increasing environmental events driven by climate change and human activity exacerbate allergy and asthma conditions, further compounded by exposure to persistent pollutants like per-and polyfluoroalkyl substances and microplastics.
Read More
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
MRD-Guided Ibrutinib Plus Venetoclax Effective in R/R CLL
June 30th 2025Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal residual disease (MRD) status.
Read More